Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02850419 | Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients(EURO-DIGNITY) | withdrawn | Phase 2 | 0 | ImunonINDUSTRY | 3 | Apr 7, 2022 | clinicaltrials |
| NCT04856475 | Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer(NeraBrain) | withdrawn | Phase 2 | 0 | Jules Bordet InstituteOTHER | 0 | Mar 2, 2022 |
| clinicaltrials |
| NCT05008510 | P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .(VERU-111) | withdrawn | Phase 2 | 0 | Veru Inc.INDUSTRY | 0 | Feb 8, 2022 | clinicaltrials |
| NCT04038489 | COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer(Breast 51) | withdrawn | Phase 2 | 0 | University of VirginiaOTHER | 1 | Nov 22, 2021 | clinicaltrials |
| NCT03634150 | Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Immune System Key LtdINDUSTRY | 1 | Oct 26, 2021 | clinicaltrials |
| NCT03940248 | Proton Accelerated Partial Breast Irradiation(APBI) | withdrawn | Phase 2 | 0 | University of CincinnatiOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT03872505 | Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer(PANDoRA) | withdrawn | Phase 2 | 0 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT02161679 | Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer | withdrawn | Phase 2 | 0 | Gilead SciencesINDUSTRY | 0 | Aug 19, 2021 | clinicaltrials |
| NCT04655183 | Study of M4344 in Combination With Niraparib | withdrawn | Phase 1 / Phase 2 | 0 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 0 | Jun 30, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT02038699 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Jazz PharmaceuticalsINDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT03863301 | MRI-guided Single Dose Preoperative Radiotherapy in Low-risk Breast Cancer(ABLATIVE-2) | withdrawn | Phase 2 | 0 | UMC UtrechtOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT00397761 | Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer | withdrawn | Phase 2 / Phase 3 | 0 | Medstar Health Research InstituteOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT02336984 | A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS | withdrawn | Phase 1 / Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 11, 2021 | clinicaltrials |
| NCT03524261 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04220476 | CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer(CIMER) | withdrawn | Phase 2 | 0 | Weill Medical College of Cornell UniversityOTHER | 0 | Sep 21, 2020 | clinicaltrials |
| NCT01818999 | Ixabepilone and SBRT For Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT03393117 | Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Breast Recontruction | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Jul 22, 2020 | clinicaltrials |
| NCT02547961 | Chimeric Antigen Receptor-Modified T Cells for Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT04149444 | A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer(TACTIC) | withdrawn | Phase 2 | 0 | AHS Cancer Control AlbertaOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT03065712 | Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT03637868 | Eribulin in Brain Metastases From HER2-negative Breast Cancer(ERIBRAIN) | withdrawn | Phase 2 | 0 | Institut Paoli-CalmettesOTHER | 1 | May 6, 2020 | clinicaltrials |
| NCT03400254 | Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")(GLACIER) | withdrawn | Phase 1 / Phase 2 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 28, 2020 | clinicaltrials |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Zhi YangOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT03323424 | Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers(IRAM) | withdrawn | Phase 2 | 0 | Institut de Cancérologie de la LoireOTHER | 1 | Jan 30, 2020 | clinicaltrials |
| NCT02018419 | Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients(MBC) | withdrawn | Phase 1 / Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03611985 | Phase I/IIa Study of Pharmacokinetics and Safety of Epidiferphane™ and Taxanes in Breast Cancer Patients | withdrawn | Phase 1 / Phase 2 | 0 | University of FloridaOTHER | 0 | Jan 13, 2020 | clinicaltrials |
| NCT02853071 | Efficacy and Safety of Estracyt® in Metastatic Breast Cancer(BEST) | withdrawn | Phase 2 | 0 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT01679743 | GRN1005 for Brain Metastases From Breast or Lung Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Nov 15, 2019 | clinicaltrials |
| NCT03185871 | Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses | withdrawn | Phase 2 | 0 | University of Wisconsin, MadisonOTHER | 0 | Nov 15, 2019 | clinicaltrials |
| NCT02538432 | Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors | withdrawn | Phase 2 | 0 | University of Maryland, BaltimoreOTHER | 0 | Nov 4, 2019 | clinicaltrials |
| NCT03794596 | A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer(IMpALA) | withdrawn | Phase 2 | 0 | The Christie NHS Foundation TrustOTHER | 0 | Jul 22, 2019 | clinicaltrials |
| NCT00960544 | Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jun 14, 2019 | clinicaltrials |
| NCT03644589 | Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer | withdrawn | Phase 2 | 0 | University of WashingtonOTHER | 1 | Apr 26, 2019 | clinicaltrials |
| NCT03058939 | Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT02988648 | A Clinical Trial Evaluating the Safety and Clinical Activity of Radioiodide (131I-) as a Novel Targeted Therapy for Metastatic Breast Cancer That Overexpresses Functional Na/I Symporter | withdrawn | Phase 1 / Phase 2 | 0 | Yale UniversityOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 18, 2018 | clinicaltrials |
| NCT01134497 | Carboplatin With or Without ZD4054 in Patients With Metastatic Breast Cancer(PLANET) | withdrawn | Phase 2 | 0 | Cardiff UniversityOTHER | 1 | May 22, 2018 | clinicaltrials |
| NCT00006123 | Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Beth Israel Deaconess Medical CenterOTHER | 1 | May 16, 2018 | clinicaltrials |
| NCT00769990 | Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Dec 13, 2017 | clinicaltrials |
| NCT00373152 | MRI in Predicting Tumor Reponse After Radiofrequency Ablation in Women With Invasive Breast Cancer | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Dec 5, 2017 | clinicaltrials |
| NCT00855114 | Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT01724242 | Vaginal DHEA for Women After Breast Cancer | withdrawn | Phase 2 / Phase 3 | 0 | Hadassah Medical OrganizationOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT03032614 | Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients | withdrawn | Phase 2 | 0 | The University of Texas Health Science Center at San AntonioOTHER | 0 | Oct 10, 2017 | clinicaltrials |
| NCT02651610 | Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer | withdrawn | Phase 2 / Phase 3 | 0 | Peregrine PharmaceuticalsINDUSTRY | 1 | Jul 11, 2017 | clinicaltrials |
| NCT01361945 | AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Texas Tech University Health Sciences Center, El PasoOTHER | 0 | May 9, 2017 | clinicaltrials |
| NCT01227408 | Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | May 2, 2017 | clinicaltrials |
| NCT00397501 | BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain | withdrawn | Phase 1 / Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Apr 21, 2017 | clinicaltrials |
| NCT02685306 | A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer | withdrawn | Phase 2 | 0 | Peregrine PharmaceuticalsINDUSTRY | 0 | Mar 9, 2017 | clinicaltrials |
| NCT01640847 | MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases | withdrawn | Phase 2 | 0 | ImunonINDUSTRY | 0 | Feb 7, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Apr 7, 2022source: clinicaltrials